Italia markets open in 7 hours 23 minutes

Organovo Holdings, Inc. (0R02.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,9800-0,0308 (-3,05%)
Alla chiusura: 06:39PM GMT
Schermo intero
Chiusura precedente1,0108
Aperto0,9800
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,9800 - 0,9800
Intervallo di 52 settimane0,9800 - 2,3186
Volume45
Media Volume674
Capitalizzazione548.526
Beta (5 anni mensile)0,91
Rapporto PE (ttm)N/D
EPS (ttm)-1,3150
Prossima data utili08 feb 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Organovo to Participate in the H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co

  • GlobeNewswire

    Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

    SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral

  • GlobeNewswire

    Organovo Announces FXR Program

    Lead Molecule Poised for Phase 2 in IBDSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced a clinical program for FXR 314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after da